Gedatolisib is an experimental drug for treatment of cancer in development by Celcuity, Inc. The mechanism of action is accomplished by binding the different p110 catalytic subunit isoforms of PI3K and the kinase site of mTOR. From Wikipedia
The findings position the company to seek FDA approval in Q4 2025 following a surge in its market valuation.
